Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Head and Neck Neoplasms × nimotuzumab × Clear all

Phase

Status

Completed 2 Withdrawn 1 Unknown 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Squamous Cell Carcinoma 4 Esophageal Neoplasms 2 Carcinoma 2 Lung Neoplasms 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma 1

Interventions

Cisplatin 9 Cetuximab 8 pembrolizumab 6 Radiotherapy 6 Fluorouracil 6 Carboplatin 5 Radiotherapy, Intensity-Modulated 4 Nivolumab 4 epacadostat 3 Radiation 3 Venlafaxine Hydrochloride 2 Surveys and Questionnaires 2 Panitumumab 2 Paclitaxel 2 Ketamine 2 Docetaxel 2 zimberelimab 1 vandetanib 1 tislelizumab 1 temsirolimus 1 ruxolitinib 1 plerixafor 1 nimotuzumab 1 linrodostat 1 fosbretabulin 1 fluoromisonidazole 1 fludarabine phosphate 1 fludarabine 1 elgemtumab 1 dl1520 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01345084 2025-03-28

NICAP

Eurofarma Laboratorios S.A.

Phase 3 Withdrawn

Carcinoma, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡